Verify any claim · lenz.io
Claim analyzed
Health“As of April 2026, the World Health Organization has classified oral contraceptives (birth control pills) as Group 1 carcinogens, indicating sufficient evidence of a link to cancer, particularly breast and cervical cancers.”
The conclusion
The claim contains a factual core but overgeneralizes and misattributes in ways that materially distort the picture. IARC — the WHO's cancer research agency, not the WHO itself — classified specifically combined estrogen-progestogen oral contraceptives as Group 1 carcinogens, not all "birth control pills." Progestogen-only pills carry a different, lower classification. The claim also omits that these same pills have well-documented protective effects against ovarian and endometrial cancers, presenting a one-sided risk profile.
Based on 24 sources: 11 supporting, 4 refuting, 9 neutral.
Caveats
- The Group 1 classification applies only to combined estrogen-progestogen oral contraceptives, not to all birth control pills; progestogen-only pills are classified as Group 2B (possibly carcinogenic).
- The classification is made by IARC (International Agency for Research on Cancer), a semi-autonomous WHO research body, and represents a hazard identification — not a WHO clinical recommendation or risk-benefit assessment.
- The claim omits that combined oral contraceptives are also associated with significant protective effects against ovarian and endometrial cancers, presenting an incomplete and one-sided cancer risk profile.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
Combined oral contraceptives are carcinogenic to humans (Group 1). There is also conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. More than 10 cohort and 50 case–control studies have assessed the relationship between use of combined oral contraceptives and the risk for breast cancer. The weight of the evidence suggests a small increase in the relative risk for breast cancer among current and recent users, which is, however, unrelated to duration of use or type or dose of preparation. By 10 years after cessation of use, the risk of women who used oral contraceptives appears to be similar to that of women who never used them. Five cohort and 16 case–control studies of use of combined oral contraceptives and invasive cervical cancer have been published; these consistently show a small increase in relative risk associated with long duration of use.
Overall, however, these studies have provided consistent evidence that the risks of breast and cervical cancers are increased in women who use oral contraceptives, whereas the risks of endometrial, ovarian, and colorectal cancers are reduced. Naturally occurring estrogen and progesterone stimulate the development and growth of some cancers (e.g., cancers that express receptors for these hormones, such as breast cancer). Because birth control pills contain synthetic versions of these female hormones, they could potentially also increase cancer risk. In addition, oral contraceptives might increase the risk of cervical cancer by changing the susceptibility of cervical cells to persistent infection with high-risk HPV types.
Combined estrogen-progestogen oral contraceptives: carcinogenic to humans (Group 1). Agents classified in Group 1 have sufficient evidence of carcinogenicity in humans. The classification is based on sufficient evidence from epidemiological studies.
The evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium.
A study carried out by the World Health Organization has produced the first compelling evidence of a long suspected link between the contraceptive pill and cervical cancer... prolonged use of the oral contraceptive pill increased the risk of cervical cancer up to fourfold, but only in women who carry the human papillomavirus (HPV).
It's not true that the WHO has 'just' classified the pill as a carcinogen... In fact, the International Agency for Research on Cancer (IARC) – the WHO's French-headquartered cancer agency – has included certain contraceptive pills on its list of substances 'carcinogenic to humans' since 2005. Only the combined pill is included on the WHO's so-called Group 1... The mini pill is currently categorised in the IARC's Group 2B... Several studies, however, have found that both of these pills slightly increase the risk of breast cancer in women.
The International Agency for Research on Cancer, a WHO group... in 1999 classified the pill as a carcinogen because it said there’s sufficient evidence demonstrating it causes some types of cancer. The agency reaffirmed that finding in 2008, when it determined there’s sufficient evidence the pills can cause breast, cervical and liver cancer.
The authors found that compared with women who never used hormonal contraception, the overall relative risk of invasive breast cancer among women who were current or recent users of any hormonal contraception was 1.20... Relative risk increased with duration of use.
Taking birth control pills for 5 or more years might make you more likely to get cervical cancer. The longer you use them, the higher your risk.
Oral contraceptive pills show a complex association with cancer risk. They help protect against ovarian and endometrial cancers, reducing the chance of these cancers the longer they are used. At the same time, women who use oral contraceptive pills have a higher risk of cervical cancer compared to those who do not. For breast cancer, most women face no increased risk, but women with inherited BRCA1 or BRCA2 gene mutations may have a higher risk, especially with long-term use. Overall, oral contraceptive pills protect against some cancers but raise the risk of others, underscoring the importance of personalized contraceptive counselling that takes into account family and medical history.
Combined estrogen–progestogen oral contraceptives (OCs) have been classified as Group 1 carcinogens by the World Health Organization (Cogliano et al. 2005). In agreement with the IARC, the recent literature confirms an increased risk of breast cancer and cervical cancer with the use of OCs. The recent literature also confirms the IARC conclusion that OCs decrease the risk of ovarian and endometrial cancers.
Group 1: Carcinogenic to humans. Estrogen-progestogen oral contraceptives (combined) (Note: There is also convincing evidence in humans that these agents confer a protective effect against cancer in the endometrium and ovary).
Does the contraceptive pill cause cancer? The contraceptive pill slightly increases breast cancer risk, but decreases ovarian and womb cancer risk.
Studies have shown that having ever taken the pill increases your risk of breast cancer. However, your risk decreases after you go off the pill.
Combined Oral Contraceptives Are Classified as Group 1 Carcinogens by IARC. The IARC Group 1 classification means there is sufficient evidence that combined oral contraceptives (COCs) can cause cancer in humans, specifically: Increased cancer risks: COCs are associated with small increases in breast cancer and cervical cancer risk. Decreased cancer risks: COCs decrease the risk of endometrial, ovarian, and colorectal cancers. A long-term cohort study of 46,022 women in the United Kingdom showed an overall neutral balance between short- and long-term cancer risks and benefits in past COC users after 30 years of follow-up.
The World Health Organization International Agency for Research and Cancer (IARC), in June 2005, has classified combination hormone contraception and menopausal therapy as carcinogenic in humans. The IARC's distinction is to identify potential carcinogens associated with nutrition, environment and pharmaceutical products. They do not produce risk-benefit analyses for any country or population. Their conclusions are highly controversial in that no proof is presented for a causal relation of estrogens with reproductive cancer, be it plausibility according to mechanisms of action or experimental evidence in the animal model.
Combined oral contraceptives are classified by the World Health Organisation among Group 1 carcinogens for their possible relationship to liver cancer, in situ and invasive cancer of the uterine cervix and breast cancer. Patients who pursue family planning should be warned of possible carcinogenic outcomes, but it should also be explained that—in addition to sexual health advantages—preferring COCs may also decrease the risks of endometrial, colorectal and ovarian cancers.
Breast cancer: An analysis of data from more than 150,000 women who participated in 54 epidemiologic studies showed that, overall, women who had ever used oral contraceptives had a slight (7%) increase in the risk of breast cancer compared with women who had never used oral contraceptives. Cervical cancer: Women who have used oral contraceptives for 5 or more years have a higher risk of cervical cancer than women who have never used oral contraceptives.
The WHO's cancer research agency did classify the combined birth control pill which contains estrogen and progesterine as a group one carcinogen. but this isn't new despite what social media suggests the classification. was made decades. ago first outlined in a 1999 report nearly 27 years ago and later reviewed and confirmed in 2008. A group one classification. that means that according to the International Agency for Research on Cancer. the agent is classified as carcinogenic to humans. so this is the strongest evidence that we have that the agent can cause cancer.
The IARC, part of WHO, classified combined oral contraceptives as Group 1 carcinogens in 2005 (published 2007 in Volume 91), based on sufficient evidence for breast and cervical cancer risk. This classification has not changed as of 2026 and specifically notes protective effects against ovarian and endometrial cancers. No new Group 1 classification occurred in 2026.
The claim that oral contraceptives are classified as a group 1 carcinogen by the World Health Organization is true but misleading. It is easy to confirm that oral contraceptives are indeed on the WHO's list of group 1 carcinogens. These classifications are made publicly available by the WHO International Agency for Research on Cancer and can be found here. However, the presence of hazard does not in any way indicate the cancer risk, which is the actual probability that cancer will occur from exposure to the substance.
The World Health Organization (WHO) classifies combined oral contraceptives (those containing both estrogen and progestin) as Group 1 carcinogens. This category includes substances for which there is sufficient evidence of carcinogenicity in humans—like tobacco and asbestos. However, a Group 1 classification does not mean all substances within it carry the same level of risk. It simply means that a causal link has been established.
Hormonal contraceptives and hormone replacement therapies are classified as carcinogenic to humans (group 1) by the International Agency for Research on Cancer, a sub organization of the World Health Organization. Group one is the level with the highest certainty of a connection to cancer. Breast cancer: Rise in risk (20-30%) while using the pill. Cervical cancer: Small increased risk with long-term use.
In 2007, the hormonal birth control pill was officially classified as a class 1 carcinogen, meaning that there is substantial evidence to prove it has a direct effect on cancer rates in humans. This is the same classification as tobacco and UV light. Specifically, the birth control pill raises the rates for certain cancers. Breast cancer risk may rise during active use... Cervical cancer risk can be higher with long-term use.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
The evidence chain is largely sound: Sources 1, 3, 4, 7, 11, 12, 16, and 19 collectively and directly confirm that IARC — the WHO's cancer research agency — has classified combined estrogen-progestogen oral contraceptives as Group 1 carcinogens since at least 2005 (reaffirmed 2008), with the classification specifically linked to breast and cervical cancer risks. The opponent raises two inferential challenges: (1) that attributing the IARC classification to "the WHO" is a category error, and (2) that the claim overgeneralizes from "combined pills" to "oral contraceptives" broadly — both are legitimate but minor scope issues rather than fatal logical flaws, since IARC is universally described as the WHO's cancer agency (Sources 3, 6, 7, 11, 19, 20), the claim specifies "birth control pills" parenthetically (which most commonly refers to combined pills), and the WHO's own fact sheet (Source 10) does confirm elevated cervical cancer risk and conditional breast cancer risk, consistent with the Group 1 hazard classification; the claim is therefore mostly true with minor inferential imprecision regarding the WHO/IARC distinction and the scope of "oral contraceptives."
Expert 2 — The Context Analyst
The claim omits key framing: the Group 1 label is an IARC Monographs hazard classification (IARC is part of the WHO family but distinct from WHO guidance), it applies specifically to combined estrogen–progestogen oral contraceptives rather than all “birth control pills,” and IARC/WHO communications stress a mixed risk profile (small/temporary increases for some cancers alongside protective effects for ovarian/endometrial cancer and risk varying by factors like HPV/BRCA) [1][3][6][10]. With that context restored, it's not accurate as written to say “the WHO has classified oral contraceptives (birth control pills)” as Group 1 implying a broad, pill-wide breast/cervical cancer message; the more correct statement is that IARC classifies combined pills as Group 1 based on sufficient evidence for certain cancers, so the claim is misleading overall [3][6][10].
Expert 3 — The Source Auditor
High-authority primary sources from IARC/WHO's cancer agency (Source 1 inchem/IARC Vol.72; Source 3 IARC Monographs classifications list; Source 4 IARC Publications) clearly state that combined estrogen–progestogen oral contraceptives are classified as Group 1 (“carcinogenic to humans”) with sufficient evidence in humans, including evidence of increased risk for cervical cancer and a small increased risk for breast cancer (with protective effects for ovarian/endometrial cancer also noted). However, the claim is overstated/misattributed because it says “the WHO has classified oral contraceptives (birth control pills) as Group 1” (the Group system is IARC's hazard classification and applies specifically to combined pills, not all oral contraceptives), and WHO's own 2025 fact sheet (Source 10) does not present a blanket breast-cancer increase for most women, so the most trustworthy evidence supports a narrower, more qualified statement than the claim.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
The WHO's cancer research arm, IARC, has unambiguously classified combined estrogen-progestogen oral contraceptives as Group 1 carcinogens — meaning there is sufficient evidence of carcinogenicity in humans — as confirmed by Source 3 (IARC Monographs), Source 12 (American Cancer Society), and Source 11 (PMC), all of which explicitly state this classification remains in force. This Group 1 designation is directly linked to increased risks of breast and cervical cancers, as corroborated by Source 1 (inchem.org), Source 7 (PolitiFact), and Source 2 (National Cancer Institute), establishing that the claim is factually accurate and supported by a broad, authoritative, and independent consensus of scientific and medical sources.
You're sliding from “IARC (a WHO-affiliated research agency) hazard-classified combined pills as Group 1” (Source 3) to “the WHO has classified oral contraceptives as Group 1,” but WHO's own fact sheet doesn't adopt that blanket framing and explicitly says breast-cancer risk is not increased for most women—undercutting your claim that WHO is asserting “sufficient evidence” of a breast-cancer link in general (Source 10). You also overgeneralize from “combined estrogen–progestogen oral contraceptives” to “oral contraceptives (birth control pills)” broadly, even though the classification is formulation-specific and fact-checkers note progestogen-only pills are categorized differently (Source 6; Source 3), so your “factually accurate” conclusion rests on equivocation, not the motion's actual wording.
Argument against
The motion falsely attributes a WHO classification: the Group 1 “carcinogenic to humans” label is an IARC Monographs hazard classification (a WHO-affiliated research agency), not a WHO policy position, and WHO's own oral-contraceptives fact sheet frames the evidence as a “complex association” and even says “most women face no increased [breast cancer] risk,” which contradicts the motion's blanket “sufficient evidence” framing for breast cancer (Source 10, World Health Organization; Source 3, IARC Monographs). It's also misleadingly broad because IARC's Group 1 listing is explicitly for combined estrogen–progestogen pills rather than “oral contraceptives” generally, with fact-checkers noting progestogen-only pills are categorized differently (Group 2B), so the motion's wording overgeneralizes the classification and its implications (Source 6, Euronews; Source 3, IARC Monographs).
Your first objection commits a distinction without a difference: IARC is explicitly described as "the WHO's cancer agency" and its classifications are published under WHO authority, so attributing the Group 1 designation to "the WHO" is entirely accurate — as Source 3 (IARC Monographs), Source 11 (PMC), and Source 12 (American Cancer Society) all do without qualification — and the WHO's own fact sheet (Source 10) actually confirms increased cervical cancer risk and elevated breast cancer risk for BRCA mutation carriers, which is fully consistent with a "sufficient evidence" hazard classification rather than contradicting it. Your second objection is a red herring: the motion specifically says "oral contraceptives (birth control pills)" and the claim is substantiated precisely for combined pills, which are the dominant and most widely used form, and Source 6 (Euronews) itself confirms the Group 1 classification for combined pills has been in place since 2005 — so your charge of overgeneralization attacks a straw man rather than the actual, well-supported claim.